# Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

> **NCT04891770** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 103 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir Alafenamide
- **DRUG:** VIR-2218
- **DRUG:** Nivolumab
- **DRUG:** Selgantolimod

## Key facts

- **NCT ID:** NCT04891770
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-14
- **Primary completion:** 2024-01-23
- **Final completion:** 2024-07-19
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891770, "Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04891770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*